Calculate estimated dosing from body metrics and protocol. Review formulas, export results, and compare scenarios safely. Verify with your oncology team always.
| Scenario | Height (cm) | Weight (kg) | BSA (m²) | Protocol input | Estimated dose (mg) |
|---|---|---|---|---|---|
| BSA example | 170 | 70 | 1.8181 | 75 mg/m² | 136.36 |
| AUC example | 165 | 60 | 1.6583 | AUC 5, CrCl 70 | 475.00 |
| Cap example | 180 | 95 | 2.1519 | 100 mg/m², cap 200 mg | 200.00 |
Chemotherapy dosing often begins with an evidence based protocol target, then adjusts for patient size, renal clearance, and documented toxicity. Body surface area models correlate imperfectly with exposure, yet remain common for many cytotoxics. Accurate height and weight entry helps reduce arithmetic errors and supports consistent verification across teams.
The Mosteller approach estimates surface area from height and weight, then multiplies by a regimen specific mg per m² value. This produces a starting dose in milligrams. Some institutions apply caps to limit extreme doses or standardize vial usage. Any cap must follow the prescribing protocol and pharmacy policy.
For carboplatin, exposure is commonly targeted using area under the curve dosing. The Calvert formula combines the target AUC with an estimated or measured GFR or creatinine clearance plus a constant of 25. When measured clearance is available, it is generally preferred over estimates, especially at extremes of age or muscle mass.
Rounding practices vary and may reflect vial sizes, stability limits, and dose banding programs. Document the chosen rounding rule and apply it consistently. When changing rounding, separate calculation from compounding decisions, and record both the calculated dose and the prepared dose to maintain traceability for audits and safety checks.
Before administration, verify patient identifiers, protocol cycle and day, dose reductions, organ function labs, and recent toxicities. Monitor for infusion reactions, myelosuppression, renal changes, and cumulative dose limits where applicable. Use this calculator as a transparent worksheet to support double checks, not as a substitute for clinical judgment.
Common modifiers include prior grade three or four toxicities, hepatic impairment, neuropathy risk, and concurrent radiotherapy. Record planned reductions as percentages and the clinical reason, so future cycles remain consistent. If laboratory values change between ordering and administration, recalculate using the most recent verified results. When serum creatinine is unusually low, some centers apply minimum values to avoid overestimating clearance; follow local policy. Always confirm units, especially mg per m² versus mg per kg, and keep a second checker independent. Capture infusion volume, diluent, and rate limits in notes to support compounding accuracy and administration safety.
No. Many regimens still use BSA, but some use fixed doses, weight based dosing, or exposure targets. Always follow the protocol for the specific agent.
Yes. A measured clearance can better reflect renal function than estimates in some patients. Enter it when provided by your lab or nephrology service.
The constant approximates nonrenal clearance for carboplatin. It is part of the published formula and should not be modified unless your protocol explicitly states otherwise.
Policies differ. Some use actual, ideal, or adjusted weight depending on body habitus. Use the approach specified by your institution and regimen documentation.
Caps should only be applied when the protocol or local policy requires them. If a cap is used, document the cap value and the uncapped calculation.
No. This tool supports education and double checking. Final prescribing must consider labs, toxicity history, comorbidities, interactions, and current clinical guidance.
Important Note: All the Calculators listed in this site are for educational purpose only and we do not guarentee the accuracy of results. Please do consult with other sources as well.